181 related articles for article (PubMed ID: 23018486)
1. Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure.
Fragasso G; Spoladore R; Maranta F; Corti A; Lattuada G; Colombo B; Locatelli M; Salerno A; Calori G; Briceno L; Alfieri AB; Perseghin G; Margonato A
J Cardiovasc Med (Hagerstown); 2013 Jan; 14(1):49-56. PubMed ID: 23018486
[TBL] [Abstract][Full Text] [Related]
2. Effects of carvedilol on right ventricular ejection fraction and cytokines levels in patients with systolic heart failure.
Tatli E; Kurum T; Aktoz M; Buyuklu M
Int J Cardiol; 2008 Apr; 125(2):273-6. PubMed ID: 18053592
[TBL] [Abstract][Full Text] [Related]
3. Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
Nessler J; Nessler B; Kitliński M; Gackowski A; Piwowarska W; Stepniewski M
Kardiol Pol; 2008 Feb; 66(2):144-51; discussion 152-3. PubMed ID: 18344152
[TBL] [Abstract][Full Text] [Related]
4. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
[TBL] [Abstract][Full Text] [Related]
5. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M
Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927
[TBL] [Abstract][Full Text] [Related]
6. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
[TBL] [Abstract][Full Text] [Related]
7. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy.
Tatli E; Kurum T
Can J Cardiol; 2005 Mar; 21(4):344-8. PubMed ID: 15838561
[TBL] [Abstract][Full Text] [Related]
8. Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol.
Nessler J; Nessler B; Golebiowska-Wiatrak R; Palka I; Gackowski A; Kitlinski M; Melander O; Fedorowski A
Cardiol J; 2013; 20(2):144-51. PubMed ID: 23558872
[TBL] [Abstract][Full Text] [Related]
9. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.
Frantz RP; Olson LJ; Grill D; Moualla SK; Nelson SM; Nobrega TP; Hanna RD; Backes RJ; Mookadam F; Heublein D; Bailey KR; Burnett JC
Am Heart J; 2005 Mar; 149(3):541-7. PubMed ID: 15864245
[TBL] [Abstract][Full Text] [Related]
10. Restrictive left ventricular filling pattern and its effect on the clinical course of systolic heart failure in patients receiving carvedilol.
Nessler J; Nessler B; Kitliński M; Stepniewski M; Piwowarska W
Cardiol J; 2008; 15(4):329-37. PubMed ID: 18698541
[TBL] [Abstract][Full Text] [Related]
11. Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.
Fujimura M; Akaike M; Iwase T; Yoshida S; Sumitomo Y; Yagi S; Ikeda Y; Hashizume S; Aihara K; Nishiuchi T; Yasumura Y; Matsumoto T
Acta Cardiol; 2009 Oct; 64(5):589-95. PubMed ID: 20058503
[TBL] [Abstract][Full Text] [Related]
12. Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure.
Razzolini R; Tarantini G; Boffa GM; Orlando S; Iliceto S
Ital Heart J; 2004 Jul; 5(7):517-22. PubMed ID: 15487269
[TBL] [Abstract][Full Text] [Related]
13. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol.
Chen L; Meyers D; Javorsky G; Burstow D; Lolekha P; Lucas M; Semmler AB; Savarimuthu SM; Fong KM; Yang IA; Atherton J; Galbraith AJ; Parsonage WA; Molenaar P
Pharmacogenet Genomics; 2007 Nov; 17(11):941-9. PubMed ID: 18075464
[TBL] [Abstract][Full Text] [Related]
14. Carvedilol reduces elevated B-type natriuretic peptide in dialyzed patients without heart failure: cardioprotective effect of the beta-blocker.
Kojima M; Sato K; Kimura G; Ueda R; Dohi Y
J Cardiovasc Pharmacol; 2007 Apr; 49(4):191-6. PubMed ID: 17438403
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
Wali RK; Iyengar M; Beck GJ; Chartyan DM; Chonchol M; Lukas MA; Cooper C; Himmelfarb J; Weir MR; Berl T; Henrich WL; Cheung AK
Circ Heart Fail; 2011 Jan; 4(1):18-26. PubMed ID: 21036889
[TBL] [Abstract][Full Text] [Related]
16. N-terminal prohormone brain natriuretic peptide plasma levels in heart failure are affected both directly and indirectly by carvedilol.
Kallistratos MS; Dritsas A; Laoutaris ID; Cokkinos DV
Angiology; 2008; 59(3):323-8. PubMed ID: 18388105
[TBL] [Abstract][Full Text] [Related]
17. Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure.
Alfieri AB; Briceno L; Fragasso G; Spoladore R; Palloshi A; Bassanelli G; Montano C; Arioli F; Cuko A; Ruotolo G; Margonato A
J Cardiovasc Pharmacol; 2008 Jul; 52(1):49-54. PubMed ID: 18594474
[TBL] [Abstract][Full Text] [Related]
18. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
19. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
[TBL] [Abstract][Full Text] [Related]
20. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR
Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]